Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with diabetes. Susvimo, also ...

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...

Study from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...